Scope of US Patent 11,345,677: Citric acid cocrystals, XRD/DSC-defined forms, and IDH1/IDH2 mutant cancer use claims
US Drug Patent 11,345,677 claims a narrowly defined cocrystal of a specific “compound of formula (I)” with citric acid, optionally with water, with identity defined by X-ray powder diffraction (XRD) peak positions and DSC thermal behavior. The claim set then expands protection to (i) pharmaceutical compositions containing the cocrystal and (ii) method-of-treatment of cancers characterized by IDH1 and/or IDH2 mutations, including specific mutation substitutions, tumor types, and clinical states (refractory/relapsed and newly diagnosed/previously untreated).
Because the claim 1 core is form-specific (crystal identity) and the downstream method claims are mutation- and indication-specific, the practical protection and launch risk profile is driven by whether a generic or competitor can (a) practice the same drug substance identity or (b) use a substitute form/formulation while avoiding infringement.
What does US 11,345,677 claim: citric acid cocrystal of formula (I) with XRD/DSC identifiers?
Claim 1 foundation: the protected drug substance is a cocrystal, not “just” formula (I)
- Claim 1: “A cocrystal comprising a compound of formula (I) and citric acid.”
- This establishes product/substance coverage that can be infringed by making, using, selling, offering for sale, or importing the specified cocrystal form.
Key scope implication: If an accused product uses formula (I) as a free base/salt or a different coformer, it does not meet claim 1 unless the accused solid is a cocrystal comprising citric acid as the coformer.
Claims 2–6: XRD-reflection fingerprint narrows the “cocrystal” to specific diffraction peak sets
Claims 2–6 define the cocrystal “characterized by” an XRD pattern acquired in reflection mode with:
- Tolerance: peak position ± 0.2° 2-theta
- Peak set: selected from {5.7, 8.4, 11.4, 15.8, 18.1, 19.2, 21.1, 22.5, 23.0}
Coverage structure:
- Claim 2: at least one peak present from that set including a specific group list (as written, includes single-peak characterization).
- Claims 3–5: requires at least two, at least three, at least four peak positions respectively from the set.
- Claim 6: requires 5.7 and 8.4, plus at least three additional peaks from the remaining set.
Key scope implication: These claims are high-value because they turn a general “cocrystal” into a measurable, testable solid-state identity. A design-around strategy for competitors typically focuses on making a different polymorph/cocrystal (different peak positions) or using a form that does not meet the peak inclusion/tolerance requirements.
Claim 7: DSC endothermic onset temperature adds a second orthogonal identity test
- Claim 7: DSC thermogram includes an endothermic peak with an onset of 170.6°C ± 2.0°C.
Key scope implication: This is another objective discriminator. A competitor that matches XRD peaks but shifts DSC behavior (or vice versa) may avoid narrow dependent coverage (claims 2–7), but still could face exposure under claim 1 unless the evidence shows it is not the citric-acid cocrystal.
Claims 8–10: water presence and stoichiometry further constrain form identity
- Claim 8: cocrystal further comprises water.
- Claim 9: molar ratio compound of formula (I) : citric acid : water = 2:1:1
- Claim 10: unit cell described as 4 molecules of formula (I), 2 citric acid molecules, and 2 water molecules per unit cell.
Key scope implication: These dependent claims target specific hydration. If a product is an anhydrous citric-acid cocrystal, a partially hydrated version, or a different hydrate stoichiometry, it may avoid claims 8–10 while still potentially implicating claim 1 and the XRD-only claims depending on the actual diffraction pattern.
How broad is the protection: are there multiple “infringement pathways” or only one?
Two-layer structure
- Substance layer (claim 1): any citric acid cocrystal of formula (I).
- Form-definition layer (claims 2–10): specific XRD fingerprints, DSC onset, and hydration/stoichiometry.
Practical enforcement profile
- If a party can show the accused solid is a citric-acid cocrystal of formula (I), claim 1 is the most direct hook.
- If the party can further show the accused solid matches the specific XRD peaks and/or DSC onset and/or hydration, dependent claims provide stronger, more objective infringement anchors.
Resulting risk: For competitors, the hardest path is not merely substituting “salt vs cocrystal,” but matching the exact solid-state identity characterized by the claimed measurement criteria.
What formulation claims exist in US 11,345,677: pharmaceutical composition coverage?
Claim 11
- Pharmaceutical composition comprising a therapeutically effective amount of the cocrystal of claim 1 and one or more excipients.
Scope implication: Claim 11 is broad over typical excipients and dosage forms as long as the active is the claimed cocrystal of claim 1. It does not appear to limit to a particular dosage form in the text provided.
What method-of-treatment claims exist: IDH1/IDH2 mutant cancers and mutation-specific use?
Core method claim: claim 12
- Administer a therapeutically effective amount of the cocrystal of claim 1 to a patient with cancer characterized by:
- IDH1 mutation, or
- IDH2 mutation, or
- combination.
Key scope implication: This is an indication-and-biomarker claim. It can be infringed by practicing the treatment regimen in the relevant patient population using the claimed cocrystal, regardless of whether the competitor uses a different excipient set, provided the active substance is the claimed cocrystal.
Mutation-specific dependent claims (claims 13–20)
- IDH1 R132X (claim 14)
- R132H or R132C (claim 15)
- IDH2 R140X (claim 16)
- R140Q, R140W, or R140L (claim 18)
- IDH2 R172X (claim 19)
- R172K or R172G (claim 20)
Scope implication: These claims tightly couple to specific substitutions. If a generic’s intended use is limited to other IDH1/IDH2 variants not covered by the enumerated substitutions, it can reduce method-claim exposure, but claim 12 still covers “IDH1 mutation” and “IDH2 mutation” generally. The dependent claims narrow further; the independent mutation language still matters.
Tumor-type dependent claims (claims 21–24)
Claim 21 lists a wide set of cancers; claim 22 narrows to glioma, with additional subclassification:
- Low grade glioma or secondary high grade glioma (claim 23)
- Secondary high grade glioma = glioblastoma (claim 24)
Scope implication: This set supports broad commercial coverage across multiple IDH-driven oncology indications, with explicit glioma subclass coverage.
Clinical state dependents (claims 25–26)
- Refractory or relapsed (claim 25)
- Newly diagnosed or previously untreated (claim 26)
Scope implication: These provisions reduce the ability to argue “not the target population.”
Combination therapy dependent claim (claim 27)
- Co-administering an additional therapy.
Scope implication: This anticipates real-world regimens and reduces design-around by combination.
Prior-therapy population (claim 28)
- Patient previously administered cancer therapy.
Scope implication: Again broadens the eligible patient set.
Does US 11,345,677 constrain dosage and administration schedule?
Dose ranges and per-day amounts (claims 29–31)
- Claim 29: about 10, 25, 50, 100, 200, or 300 mg/day (based on formula (I) amount).
- Claim 30: specifically about 10 mg or 50 mg twice per day.
- Claim 31: glioma is a low grade glioma (ties to claim 23).
Scope implication: Claims 29–31 are administration-specific. If a competitor uses an off-range dose or an alternate schedule, it may seek to avoid these dependent claims. However, claim 12 is not limited by dose in the provided claim text and can still be asserted if therapeutically effective dosing is used with the same active.
How many different “claim families” are embedded in US 11,345,677?
From the claim language provided, US 11,345,677 effectively contains three embedded infringement themes:
- Solid-state identity: citric acid cocrystal defined by XRD peaks and DSC onset (claims 1–7).
- Hydration/stoichiometry: water content and ratios (claims 8–10).
- Clinical use: mutation-specific oncology treatment (claims 12–31), including tumor type, disease state, and dosing.
This structure typically indicates the patent was drafted to cover:
- substitution of excipients is unlikely to avoid,
- substitution of polymorph/hydrate may partially avoid,
- substitution of alternative IDH indications may avoid method claims depending on exact biomarker matching, but claim 12’s broad IDH1/IDH2 mutation language is a significant barrier.
What is the likely patent landscape around US 11,345,677 (US-only) for cocrystal + IDH use?
The information supplied contains the claim text only and does not provide:
- the patent title,
- the assignee,
- application/publication numbers,
- filing/priority dates,
- jurisdictions covered,
- other related patents in the same family,
- the identity of “compound of formula (I)”.
Without those identifiers, a complete, accurate mapping of the surrounding US patent estate and litigation landscape cannot be produced.
Key design-around and infringement pressure points
For generic or competitor solid-state substitution
- If they use formula (I) + a different coformer: likely avoids claim 1.
- If they use citric acid but produce a different diffraction fingerprint: may avoid claims 2–6 and the water/DSC dependents depending on the mismatch.
- If they use the same cocrystal form but with different hydration level: may avoid claims 8–10 while leaving exposure under claim 1 and potentially claim 2–7 depending on the XRD match.
For method-of-use strategies
- Restricting to cancers not listed in claim 21 and not qualifying as glioma subclasses can reduce dependent-claim exposure.
- However, the independent method claim 12 covers “cancer characterized by presence of an IDH1 mutation, IDH2 mutation, or combination.” That baseline biomarker language is hard to avoid if the product label or practice targets IDH mutant disease with the claimed active.
For combination therapy
- Claim 27 explicitly permits co-administration with additional therapy, reducing an easy “combo-therapy carveout” argument.
Key takeaways
- US 11,345,677 protects an IDH1/IDH2 oncology active in the form of a citric acid cocrystal of formula (I) (claim 1).
- Dependent claims convert “cocrystal” into a testable solid identity via XRD peak sets (claims 2–6) and DSC endotherm onset at 170.6°C ± 2.0°C (claim 7).
- The patent adds hydration constraints and stoichiometry (claims 8–10), narrowing protection to specific water-bearing forms.
- Downstream claims broadly cover pharmaceutical compositions (claim 11) and method-of-treatment of cancers defined by IDH1/IDH2 mutations, with detailed dependent coverage for specific mutations, tumor types (including glioma/glioblastoma), disease state, and dosing schemes.
FAQs
1) Can a competitor avoid infringement by switching from citric acid to another coformer?
Yes, switching coformer avoids claim 1’s requirement that the cocrystal comprises citric acid with formula (I).
2) If the competitor matches XRD peaks but not DSC onset at 170.6°C ± 2°C, what claims are impacted?
Claims that require the DSC endothermic onset (claim 7 and dependents) are avoidable; claim 1 can still remain at issue if the material is still the claimed citric-acid cocrystal of formula (I).
3) Does claim 12 require a specific dosage amount?
No dose limit is stated in the provided text of claim 12; dose-specific constraints appear in dependent claims 29–31.
4) Are glioma patients covered even when disease is low grade?
Yes. The claim tree includes glioma and further includes low grade glioma (claims 22–23 and claim 31).
5) Does combination therapy avoid the method-of-use claim?
No. Claim 27 expressly includes co-administering an additional therapy.
References (APA)
- United States Patent 11,345,677 (claims provided by user).
